603658.SS
Strong BuyFull HouseAutobio Diagnostics Co., Ltd. · Healthcare · China · $2.9B
CNY 34.08 +1.4% · close 30 Sep · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT AUTOBIO DIAGNOSTICS CO., LTD.
Read
Autobio Diagnostics is a leading Chinese developer and manufacturer of in vitro diagnostic (IVD) instruments and reagents, with a primary focus on immunoassay, microbiology, and biochemistry. The company possesses a strong competitive moat driven by its advanced chemiluminescence immunoassay (CLIA) technology and a massive installed base in Chinese hospitals. It is a key driver of domestic import substitution in China's rapidly growing clinical diagnostics market.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.4B | 4.4B | 4.5B | 4.2B | -1.6% | 4.2B | 4.4B | 4.9B | 7.4% |
| EPS (CNY) | 2.00 | 2.10 | 2.07 | 1.87 | -2.2% | 1.72 | 1.89 | 2.12 | 6.4% |
| Shares | 586.3M | 586.3M | 581.0M | 571.4M | -2.5% | 571.4M | — | — | — |
| Debt | 132.5M | 723.2M | 549.0M | 59.1M | -23.6% | 52.2M | — | — | — |
| Equity | 7.8B | 8.5B | 8.6B | 8.9B | 4.7% | — | — | — | — |
| Op CF | 1.6B | 1.5B | 1.3B | 1.3B | -4.9% | 1.1B | — | — | — |
| Inv CF | -978.7M | -787.2M | -1.2B | -415.4M | — | — | — | — | — |
| Fin CF | -218.3M | -337.0M | -1.2B | -796.3M | — | — | — | — | — |
Calmer than 84% of stocks we rank over the past year (24% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603658.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 603658.SS | Autobio Diagnostics Co., Ltd.(you) | $2.9B | 90 | Strong Buy |
| 002901.SZ | Double Medical Technology Inc. | $2.5B | 70 | Buy |
| 1187.HK | Cofoe Medical Technology Co.,Ltd. | $913M | 92 | Strong Buy |
| 688016.SS | Shanghai MicroPort Endovascular MedTech Co., Ltd. | $1.6B | 75 | Buy |
| 300832.SZ | Shenzhen New Industries Biomedical Engineering Co., Ltd. | $5.6B | 76 | Buy |
| 603387.SS | Getein Biotech, Inc | $742M | 92 | Strong Buy |
| 600587.SS | Shinva Medical Instrument Co.,Ltd. | $1.2B | 79 | Buy |
| 002223.SZ | Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. | $3.9B | 65 | Buy |
| 2190.HK | Zylox-Tonbridge Medical Technology Co., Ltd. | $875M | 83 | Strong Buy |
| 688410.SS | SWS Hemodialysis Care Co., Ltd. | $651M | 87 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 52.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.